Aldehyde dehydrogenase and HSP90 co-localize in human glioblastoma biopsy cells. by Rappa, F. et al.
This article appeared in a journal published by Elsevier. The attached
copy is furnished to the author for internal non-commercial research
and education use, including for instruction at the authors institution
and sharing with colleagues.
Other uses, including reproduction and distribution, or selling or
licensing copies, or posting to personal, institutional or third party
websites are prohibited.
In most cases authors are permitted to post their version of the
article (e.g. in Word or Tex form) to their personal website or
institutional repository. Authors requiring further information





Aldehyde dehydrogenase and HSP90 co-localize in human
glioblastoma biopsy cells
F. Rappa a, F. Cappello b, M.-E. Halatsch c, A. Scheuerle d, R.E. Kast e,*
aDepartment of Experimental Biomedicine and Clinical Neurosciences, University of Palermo, Palermo, Italy
b Euro-Mediterranean Institute of Science and Technology, Department BIONEC, University of Palermo, Palermo, Italy
cDepartment of Neurosurgery, University of Ulm, Germany
dDepartment of Neuropathology, University of Ulm, Germany
eDepartment of Psychiatry, University of Vermont, 22 Church Street, Burlington, VT 05401, USA
a r t i c l e i n f o
Article history:
Received 24 September 2012
Accepted 12 November 2012









a b s t r a c t
The concept of a stem cell subpopulation as understood from normal epithelial tissue or bone marrow
function has been extended to our understanding of cancer tissue and is now the target of treatment
efforts speciﬁcally directed to this subpopulation. In glioblastoma, as well as in other cancers, increased
expression of aldehyde dehydrogenase (ALDH) has been found localized within a minority sub-
population of tumor cells which demonstrate stem cell properties. A separate body of research associ-
ated increased expression of heat-shock protein-90 (HSP90) with stem cell attributes. We present here
results from our initial immunohistochemistry study of human glioblastoma biopsy tissue where both
ALDH and HSP90 tended to be co-expressed in high amounts in the same minority of cells. Since 12% of
all cells in the six biopsies studied were ALDH positive and 17% were HSP90 positive, by chance alone 2%
would have been expected to be positive for both. In fact 7% of all cells simultaneously expressed both
markers-a signiﬁcant difference (p ¼ 0.037). That two previously identiﬁed proteins associated with stem
cell attributes tend to be co-expressed in the same individual glioblastoma cells might have clinical
utility. Disulﬁram, used to treat alcoholism for half-a century now, is a potent ALDH inhibitor and the old
anti-viral drug ritonavir inhibits HSP90. These should be explored for the potential to retard aspects of
glioblastoma stem cells’ function subserved by ALDH and HSP90.
 2012 Elsevier Masson SAS. All rights reserved.
1. Preamble
“Upon this, one has to remark that men ought either to be well-
treated or crushed entirely. They can avenge themselves of
lighter injuries. Of more serious ones they cannot...” otherwise
known as “Never do an enemy a small injury.” Machiavelli, ca.
1469-1527
2. Introduction
Glioblastoma remains one of the most aggressive and difﬁcult to
treat of all human cancers. Despite extensive surgical resection fol-
lowed by radiotherapy and temozolomide (TMZ), an oral methylating
chemotherapy agent, glioblastoma usually recurs within the original
treatment area. Patientsusually surviveonly1e2yearsafterdiagnosis.
Local recurrence is seen even in those patients whose original tumor
has been widely resected, with no visible tumor remaining on MRI
scan. The development of more effective therapies for glioblastoma
must incorporate strategies which address recurrence from residual
single cells or microscopic cell clusters. Part of glioblastoma’s
resistance to chemotherapy and irradiation derives, as in the
Preamble, from many compensatory growth enhancing changes that
are triggered by current mainstay treatments [1e5].
Glioblastoma’s repopulation of the surgical cavity even after
intensive anti-tumor therapies involves the existence of a tumor
stem cell sub-population that is a prime locus of the growth-
enhancing compensatory changes triggered by treatment [6e9].
This stem cell hypothesis of glioblastoma (and cancer generally)
states that there exists a minority of relatively quiescent and
undifferentiated cells that, as with marrow haematopoetic stem
cells, produce a variety of downstream daughter cell types as well
as self-renew as other stem cells [6,8,9]. Non-stem cells constitute
the bulk of a tumor. The attributes of stemness are thought to be
relative quiescence, cytotoxic chemotherapy resistance, higher
clonogenic and tumor initiation capacities than the non-stem
population [6,8,9].
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Our team has been pursuing the potential of conceptually new
avenues of approach. We, along with others, are exploring the
potential of inherently non-cytotoxic, currently marketed drugs to
inhibit growth promoting or apoptosis resistance pathways that have
been identiﬁed as active in glioblastoma (recent examples: [10e15]).
We envision these noncytotoxic interventions as adjuncts to improve
the current standard Stupp Protocol [7] of maximal resection, TMZ,
and irradiation.
Aldehyde dehydrogenase (ALDH) is expressed in higher amounts
in a sub-set of cells within glioblastomas that show stem cell attri-
butes like cytotoxic chemotherapy resistance and higher clonogenic
capacity compared to the ALDH low expressing cells [10e12]. ALDH
is considered a marker of stem cells in many other cancers [16e18].
We have also been interested in heat-shock protein-90 (HSP90),
an ATP hydrolyzing, 90 kDa protein found as a homodimer, upre-
gulated and playing a prominent role in cancer generally [19] and
glioblastomas speciﬁcally [20e24]. Functioning to stabilize and
correctly fold many client proteins, HSP90 is crucial to cell prolif-
eration, cell survival, and most importantly here, for stem cell
function. Core mediators of glioblastoma growth like endothelial
nitric oxide synthase (eNOS) [25], epidermal growth factor receptor
(EGFR) [26,27], and transforming growth factor-beta (TGF-beta) are
HSP90 client proteins [28]. HSP90 is overexpressed speciﬁcally in
the cancer stem cell sub-population [29,30].
Since we have separate bodies of evidence of both ALDH and
HSP90 being speciﬁcally overexpressed in stem cell subpopula-
tion(s), we set out to determine if one and the same stem cell
expressed both or if ALDH and HSP90 demarked different stem cell
sub-populations in glioblastoma. We indeed found that high
expression of ALDH and high expression of HSP90 tended to co-
occur in the same cells beyond what one would expect from
chance alone in human glioblastoma biopsy tissues. Some potential
treatment implications of these ﬁndings are given in the Discussion
section below.
3. Methods
Formalin ﬁxed, parafﬁn-embedded sections of glioblastoma
biopsies were run for immunoﬂuorescence, using primary anti-
bodies anti-ALDH1A1 and HSP90a/b, using standard protocols. In
brief, after deparafﬁnation and rehydration, tissue sections were
blocked with 3% BSA in PBS for 30 min and incubated with the ﬁrst
primary antibody overnight, one night for each antibody (goat
polyclonal antibody ALDH1A1, dilution 1:100, Santa Cruz Biotech-
nology Inc., Santa Cruz, CA, USA, Cat. N. sc-22589; mouse mono-
clonal antibody HSP90a/b, dilution 1:100, Santa Cruz Biotechnology
Inc., Cat. N. sc-13119). After washing with PBS, slides were further
incubated with ﬂuorescent secondary antibodies for 1 h at room
temperature (Goat anti-mouse IgG TRITC-conjugated secondary
antibody, dilution 1:50, SigmaeAldrich, Saint Louis, MO, USA, Cat.
N.T-5393; Donkey anti-goat IgG-FITC-conjugated secondary anti-
body, dilution 1:50, Santa Cruz Biotechnology Inc., Cat. N. sc-2024).
Finally, nuclei were stained for 15 min with Hoechst 33342 (dilu-
tion 1:1000 in PBS, SigmaeAldrich, Cat. N. B-2261). Further method
details are available from the authors.
Slides were observed on a Leica CTR5000 ﬂuorescent micro-
scope. All observations were made at 400magniﬁcation (HPF) by
two independent observers (FR and FC) and the means of duplicate
counts were used for statistical analyses.
Data obtained from immunoﬂuorescence evaluations were
plotted using Microsoft Excel software (Microsoft Italia, Milan,
Italy). Statistical analyses were performed using Statview 5.0 (SAS
Institute Inc., Cary, NC, USA). Mean and standard deviation (SD) of
data were calculated. Moreover, correlation analyses were per-
formed using the Spearman rank correlation method. Probability
values of p < 0.05 were considered signiﬁcant. Finally, to have an
indication on the variability of immunoreactivity data obtained by
the different observers, the coefﬁcient of variation was calculated
using both the interobserver and intraobserver kappa statistics.
4. Results
Table 1 shows the percentage of cells positive for ALDH1A1, for
HSP90, and percentage of cells positive to both markers (“Merge”).
In particular, ALDH1A1 was present in a percentage of cells
between 6.6 and 15.6 (mean: 12%), while HSP90 was present in
a percentage of cells between 11.2 and 20.2 (mean: 17%). Between
5.2 and 10.8% (mean: 7%) of glioblastoma cells were positive to both
proteins. Fig. 1 shows an H & E stained glioblastoma biopsy from
one of our six cases. Fig. 2 shows nearby slices stained for ALDH1A1,
HSP90, and an enlarged merged micrograph where yellow or
orange hues indicate staining for both ALDH and HSP90.
Statistical analyses (Table 1) showed the presence of a signiﬁ-
cant correlation between ALDHA1 and HSP90 (r ¼ þ0.838,
p ¼ 0.0371). Despite the small cohort of subjects, the “r” value is
strong. Finally, inter-observer kappa statistics showed a value of
0.85 and intra-observer kappa statistics a value of 0.95.
5. Discussion
The concept of a stem cell subpopulation within a tumor is the
subject of much effort to reﬁne and deﬁne. Cancer stem cells,
including those of glioblastoma are generally thought to be
Table 1
Percentage of cells positive for each marker (ALDH1A1, HSP90) and of double
positive cells (merge). The percentage of positive cells was calculated on 10 HPF
(400) in each sample by two independent observers [FR & FC]; mean of observa-
tions is indicated in the table. The graph shows a signiﬁcant correlation between
ALDHA1 and HSP90 (r ¼ þ0.838, p ¼ 0.0371) in examined samples.
Patients ALDH1A1 Hsp90 Merge Expected if
no association
121 10.45% 18.60% 5.46% 2%
131 6.60% 11.23% 5.18% 1%
141 15.60% 19.54% 10.78% 3%
202 10.80% 16.73% 7.66% 2%
252 13.58% 20.16% 7.26% 3%
273 12.00% 14.80% 6.16% 2%
-,839 4,054 -,839 -,207 ,8462
,729 ,237 ,838 3,076 ,0371
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a CD133þ subpopulationwithin a tumor that is relatively quiescent
and chemotherapy resistant, forming a reservoir of cells with high
ALDH activity, with strong self-renewal capabilities, that is less
differentiated than the majority population, that can generate
semi-differentiated highly proliferative non-stem tumor cells that
are CD133 negative and have lower expression of ALDH [16e18].
The tendency we documented here are suggestive of an association
beyond chance alone for high HSP90 expression to co-localize
within the same cells as does high ALDH expression, supporting
previous contentions of others that HSP90 is also a stem cell marker
in glioblastoma. Beyond being simply markers of stem cell
attributes, ALDH and HSP90 potentially function to mediate aspects
of stem cell behavior.
Already in 1990 both human glioblastoma growing in nudemice
and human glioblastoma biopsy tissue were shown to have greatly
increased ALDH activity [31]. Then in 2010 ALDH was shown to
facilitate clonal sphere formation in established glioblastoma cell
lines [16]. High levels of ALDH functioned to keep these cells in an
undifferentiated stem cell-like state [16].
Disulﬁram is an ALDH inhibitor marketed and in clinical use to
treat alcoholism since the 1950’s [18]. Previous in vitro research has
empirically documented augmented in vitro cytotoxicity when
disulﬁram was added to standard cancer chemotherapy agents:
cisplatin [32], TMZ [14], paclitaxel [33], gemcitabine [34,35],
docetaxel [36], cyclophosphamide [37], 5-ﬂuorouracil [38], and
doxorubicin [39].
The only clinical study we are aware of looking at disulﬁram
during human cancer treatment used grotesquely high disulﬁram
levels, over 3000 mg/day [40], while the usual dose when treating
alcoholism is 250 mg by mouth once or twice daily. This study
found no statistical beneﬁt when disulﬁram was added to cisplatin
[40] but the dropout ratewas so high in both cisplatin alone and the
cisplatin plus disulﬁram groups that data evaluation was difﬁcult.
Although not statistically signiﬁcant, the only patient to achieve
a complete remission was in the combination group [40]. A single
case study showed complete and sustained remission of a stage IV
metastatic melanoma to zinc supplemented disulﬁram [41].
Glioblastoma biopsies show immunohistochemical over-
expression of several HSP’s, among them HSP90 [42]. One of the
ﬁrst anti-HIVdrugs to come tomarketwas thenow-generic protease
inhibitor ritonavir. Ritonavir bindsHsp90with aKdof 7.8mmol/L and
partially inhibits HSP90’s chaperone function [43e46].
Although this is a weak inhibitor, it is the one we have available
currently marketed. Ritonavir has limited ability to penetrate the
bloodebrain barrier, but the common anti-fungal drug ketocona-
zole at 200 mg bymouth daily increased CSF ritonavir by 178% (95%
CI, 59%e385%), from 2.4 to 6.6 ng/mL [47]. Haupt et al. just pub-
lished a list of 64 signaling kinases that are HSP90 client proteins,
many of which have been shown to be important in giving rise to
stem cell attributes and glioblastoma growth and apoptosis
resistance-perhaps most important of them those of TGF-beta
pathway [46].
In discussing the HER group of tyrosine kinases Citri et al. said
“the dependence of ErbB-2 upon Hsp90 reveals an Achilles heel,
which opens a window of opportunity for combating cancers
driven by the ErbB/HER signaling network.” [21]. Although we
don’t agree with applicability of the term Achilles heel (glioblas-
toma, like any strong foe, has too many overlapping, cross-covering
growth stimulating pathways to have any single Achilles heel) we
do understand and agree with the utility of inhibiting HSP90’s role
in assisting EGFR and other HERmembers’ signaling. Experimental,
geldanamycin-related HSP90 inhibitors have shown anti-
glioblastoma activity in animal models [48,49] suggesting that
ritonavir might do so as well.
Our results conﬁrm in and extend to human glioblastoma biopsy
tissue previous ﬁndings of Lee et al. in xenografted cell lines from
human breast cancer [30] where ALDH and HSP90 tended to co-
localize in the stem cell sub-population.
6. Conclusions
At a high normal clinical dose of 500 mg once daily no added
burden to patients would be expected from disulﬁram use as
adjunct to the Stupp Protocol in glioblastoma treatment other than
the necessity for abstinence from alcohol. Ritonavir at 400 mg
orally twice daily did not separate from placebo side effect-wise.
Fig. 1. H & E micrograph of same glioblastoma biopsy tissue as that immunostained in
Fig. 2. Bar: 100 micron.
Fig. 2. Representative micrographs immunostained for ALDH1A1 (green) or Hsp90
(red) from same tissue block as in Fig. 1. Lower is a merging of both ALDH1A1 and
Hsp90 micrographs where cells in hues of orange or yellow (arrows) are positive for
both molecules. Bar: 100 micron. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
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Given the deadly nature of glioblastoma and the meagerness of
progress we’ve seen over the last decades it is time to try new
conceptual approaches. One such is to target growth facilitating
pathways with these two non-cytotoxic, currently marketed drugs
The minority stem cell population is more resistant to cytotoxic
drugs and irradiation than are the majority non-stem population.
We have shown that glioblastoma putative stem cells co-express
higher amounts of ALDH and HSP90 than do the non-stem pop-
ulation. As in The Preamble, on our way to crush the enemy entirely,
by depriving glioblastoma’s stem cells of those protective attributes
mediated by ALDH and HSP90wemightmake our current cytotoxic
chemotherapies less slight injuries.
7. Postscript
“Drug discovery for complex and heterogeneous tumors now
aims at dismantling global networks of disease maintenance...”
[Siegelin et al. in ref. 49, referring to glioblastoma]. Adding
disulﬁram and ketoconazole-assisted ritonavir to current
treatment of glioblastoma might prove to be a step in such
project of comprehensive dismantling.
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